Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Elisabeth Ng; Jonathan E. Shaw; Anna Wood; Louise J. Maple-Brown; Matthew JL Hare

doi:10.31128/AJGP-07-21-6057

Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Elisabeth Ng, Jonathan E. Shaw, Anna Wood, Louise J. Maple-Brown, Matthew JL Hare

CDU Higher Degree by Research (HDR) Cohort

Research output: Contribution to journal › Article › peer-review

Abstract

Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.

Original language	English
Pages (from-to)	513-518
Number of pages	6
Journal	Australian journal of general practice
Volume	51
Issue number	7
DOIs	https://doi.org/10.31128/AJGP-07-21-6057
Publication status	Published - Jul 2022

Access to Document

10.31128/AJGP-07-21-6057

Cite this

@article{e96ef864143241ae97dcbd8d63b0fc2c,

title = "Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes",

abstract = "Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.",

author = "Elisabeth Ng and Shaw, {Jonathan E.} and Anna Wood and Maple-Brown, {Louise J.} and Hare, {Matthew JL}",

year = "2022",

month = jul,

doi = "10.31128/AJGP-07-21-6057",

language = "English",

volume = "51",

pages = "513--518",

journal = "Australian journal of general practice",

issn = "2208-794X",

publisher = "Royal Australian College of General Practitioners",

number = "7",

}

TY - JOUR

T1 - Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

AU - Ng, Elisabeth

AU - Shaw, Jonathan E.

AU - Wood, Anna

AU - Maple-Brown, Louise J.

AU - Hare, Matthew JL

PY - 2022/7

Y1 - 2022/7

N2 - Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.

AB - Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.

UR - http://www.scopus.com/inward/record.url?scp=85133286535&partnerID=8YFLogxK

U2 - 10.31128/AJGP-07-21-6057

DO - 10.31128/AJGP-07-21-6057

M3 - Article

C2 - 35773162

AN - SCOPUS:85133286535

VL - 51

SP - 513

EP - 518

JO - Australian journal of general practice

JF - Australian journal of general practice

SN - 2208-794X

IS - 7

ER -

Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this